Rizatriptan

Medication used for the treatment of migraine headaches From Wikipedia, the free encyclopedia

Rizatriptan, sold under the brand name Maxalt among others, is a medication used for the treatment of migraine headaches.[1][3] It is taken by mouth.[1][3] It can also be applied on the tongue.[2] It is a serotonin (5-HT) 1B/1D receptor agonist (triptan).[1][2]

Trade namesMaxalt, Maxalt-MLT, Rizafilm, others
Other namesL-705126; L705126; MK-0462; MK0462; MK-462; MK462; 5-(1H-1,2,4-Triazol-1-ylmethyl)-N,N-dimethyltryptamine; 5-(1H-1,2,4-Triazol-1-ylmethyl)-DMT
AHFS/Drugs.comMonograph
MedlinePlusa601109
Quick facts Clinical data, Trade names ...
Rizatriptan
Clinical data
Trade namesMaxalt, Maxalt-MLT, Rizafilm, others
Other namesL-705126; L705126; MK-0462; MK0462; MK-462; MK462; 5-(1H-1,2,4-Triazol-1-ylmethyl)-N,N-dimethyltryptamine; 5-(1H-1,2,4-Triazol-1-ylmethyl)-DMT
AHFS/Drugs.comMonograph
MedlinePlusa601109
License data
Pregnancy
category
  • AU: B1
Routes of
administration		By mouth
Drug classSerotonin 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F receptor agonist; Antimigraine agent; Triptan
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability45%
Protein binding14%
MetabolismBy monoamine oxidase
Elimination half-life2–3 hours
Excretion82% urine; 12% feces
Identifiers
  • N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.243.719 Edit this at Wikidata
Chemical and physical data
FormulaC15H19N5
Molar mass269.352 g·mol−1
3D model (JSmol)
  • n1cncn1Cc2cc3c(cc2)[nH]cc3CCN(C)C
  • InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 checkY
  • Key:ULFRLSNUDGIQQP-UHFFFAOYSA-N checkY
  (verify)
Close

Common side effects include chest pain, dizziness, dry mouth, and tingling.[3] Other side effects may include myocardial infarction, stroke, high blood pressure, serotonin syndrome, and anaphylaxis.[3] Excessive use may result in medication overuse headaches.[3] Use is not recommended during pregnancy and breastfeeding is not recommended within 24 hours after taking a dose.[4] Rizatriptan is in the triptan class and is believed to work by activating the 5-HT1 receptor.[3]

Rizatriptan was patented in 1991 and came into medical use in 1998.[5][6] It is available as a generic medication.[4] In 2023, it was the 208th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[7][8] Rizatriptan is available in combination with meloxicam as meloxicam/rizatriptan.

Medical uses

Rizatriptan is indicated to treat acute migraine attacks with or without aura.[1][2] It does not prevent future migraine attacks.[9] A 2010 review found rizatriptan to be more efficacious and tolerable than sumatriptan.[10]

Contraindications

Rizatriptan and other triptans can cause vasoconstriction, they are contraindicated in people with cardiovascular conditions.[11]

Adverse effects

Frequent adverse effects (incidence less than 10%) are dizziness, drowsiness, asthenia/fatigue, and nausea. Clinical adverse experiences were typically mild and short-lasting (2–3 hours).[11]

Interactions

Rizatriptan has an important but complex interaction with a metabolite of the beta blocker propranolol.[12] This interaction involves the enzyme monoamine oxidase A (MAO-A).[12] Due to the interaction, the dose of rizatriptan should be reduced to 5 mg when it is combined with propranolol.[12]

Pharmacology

Mechanism of action

Further information: Serotonin receptor agonist and Triptan § Mechanism of action
More information Target, Affinity (Ki, nM) ...
Rizatriptan activities
TargetAffinity (Ki, nM)
5-HT1A48–500 (Ki)
>10,000 (EC50Tooltip half-maximal effective concentration)
40% (EmaxTooltip maximal efficacy)
5-HT1B3–138 (Ki)
1.4–234 (EC50)
74–99% (Emax)
5-HT1D1.5–138 (Ki)
1.6–16 (EC50)
83–105% (Emax)
5-HT1E87–316 (Ki)
6.8–870 (EC50)
107% (Emax)
5-HT1F138–5,370 (Ki)
4.2–2,540 (EC50)
93% (Emax)
5-HT2A>10,000 (Ki)
>10,000 (EC50)
5-HT2B257–3,090 (Ki)
3,240 (EC50)
5-HT2C>3,160 (Ki)
ND (EC50)
5-HT3>3,160 (mouse)
5-HT4>3,160 (guinea pig)
5-HT5A5,500 (rat)
5-HT6>3,160
5-HT71,860–>10,000 (Ki)
>10,000 (EC50)
α1A–α1DND
α2A–α2CND
β1–β3ND
D1–D5ND
H1–H4ND
M1–M5ND
I1, I2ND
σ1, σ2ND
TAAR1Tooltip Trace amine-associated receptor 1ND
SERTTooltip Serotonin transporterND
NETTooltip Norepinephrine transporterND
DATTooltip Dopamine transporterND
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [13][14][15][16][17][18][19]
[20][21][22][23][24][25][26]
Close

Rizatriptan acts as an agonist at serotonin 5-HT1B and 5-HT1D receptors.[27] Like the other triptans sumatriptan and zolmitriptan, rizatriptan induces vasoconstriction—possibly by inhibiting the release of calcitonin gene-related peptide from sensory neurons in the trigeminal nerve.[27]

Chemistry

Rizatriptan, also known as 5-(1H-1,2,4-triazol-1-ylmethyl)-N,N-dimethyltryptamine, is a tryptamine derivative and a 5-substituted derivative of the psychedelic drug dimethyltryptamine (DMT).[28]

The experimental log P of rizatriptan is 1.4 and its predicted log P is 1.67 to 1.77.[28][29]

History

Rizatriptan was patented in 1991 and was introduced for medical use in 1998.[5][6]

Society and culture

Brand names

Brand names include Rizalt, Rizalt RPD, Rizact (India), Rizafilm,[2] Maxalt,[1] and Maxalt-MLT.[1][30][31][32]

References

Related Articles

Wikiwand AI